JB Pharma Q4 FY25 Results: Revenue +10%, PAT ₹146cr

What JB Pharma reported for Q4 FY25

J B Chemicals & Pharmaceuticals Ltd. (JB Pharma) reported a stronger year-on-year performance in Q4 FY25, led by growth in India branded formulations and steady execution on costs. The company’s management highlighted a 10% rise in quarterly revenue to ₹949 crore and a 15% increase in net profit to ₹146 crore. Operating profitability improved, helped by better gross margins and a tighter cost structure, even as an in-licensed ophthalmology portfolio carried relatively lower margins.

Alongside the company’s earnings commentary, market trackers also reported that the consolidated profit met analyst expectations, with Bloomberg-referenced estimates for net profit at ₹142 crore. Separately, a BSE-sourced table in the provided data set showed a different income and profit series for the quarter. Since these sets are both in circulation, the most practical way to read them is as different reporting scopes and disclosures in the public domain, rather than a single unified number.

Consolidated Q4 FY25 performance in numbers

For Q4 FY25, the company reported revenue of ₹949.5 crore, up 10.2% year-on-year (and down 1.5% quarter-on-quarter, as per one summary). The revenue mix stood at 55% domestic and 45% international. Domestic revenue came in at ₹519 crore, up 11% year-on-year. International revenue rose 9% year-on-year to ₹430 crore.

On profitability, management stated operating EBITDA (excluding ESOP expenses) of ₹240 crore, up 15% year-on-year, with the operating EBITDA margin expanding 90 basis points to 25.3%. Another consolidated summary cited EBITDA of ₹226 crore (up about 14% year-on-year) with margin at 23.8% (up 86 bps year-on-year). Gross margin was reported at 66.1%, up 90-97 basis points year-on-year.

Net profit for Q4 FY25 was reported at ₹146 crore (₹145.7 crore in another line item), up 15%-16% year-on-year versus about ₹126 crore in Q4 FY24.

Domestic business: growth ahead of the market

Management indicated the domestic business continued to outperform the Indian pharma market (IPM). For the quarter, domestic revenue grew 11% year-on-year to ₹519 crore. In the same discussion, JB Pharma cited IQVIA-linked market context where the IPM grew 7%, while JB delivered 13% growth.

The company also pointed to stronger traction in chronic therapies compared with the acute portfolio. As per the earnings-call narrative shared in the input, the chronic portfolio grew 16% year-on-year in Q4 FY25 while the acute portfolio grew 10%. The ophthalmology business was reported at ₹56 crore in Q4 FY25, up 22%.

A management response in the provided text added that excluding ophthalmology, domestic growth was close to 12%, with volume growth at 6%, and the remaining growth coming from price and new introductions.

International business and CDMO contribution

International business revenue increased 9% year-on-year to ₹430 crore in Q4 FY25. Within international operations, the text noted CDMO drove growth in the quarter, with CDMO revenue cited at ₹129 crore and growth of 18%.

For the full year, management said international business grew 4% to ₹1,649 crore, while selected markets such as Russia and branded generics exports posted double-digit growth. CDMO was described as growing 3% for the year, with a stronger recovery in the second half.

Margins, expenses, and finance cost movement

The company reported a gross profit margin of 66.1% in Q4 FY25, with expansion despite the in-licensed ophthalmology portfolio. Operating leverage was also supported by expense control. Other expenditure as a percentage of sales reduced to 23.7%, down 80 basis points.

A notable change was in finance costs, which management said fell sharply to ₹1 crore in Q4 FY25 from ₹9 crore in Q4 FY24, primarily due to a reduction in gross debt. This helped protect bottom-line growth even as the quarter saw normal business seasonality.

FY25: revenue, profit, cash flows, and capital efficiency

For FY25, JB Pharma reported revenue growth of 12% to ₹3,918 crore. The domestic-to-international mix for the year was stated as 58% to 42%. Management said the domestic business witnessed 20% growth in FY25, and cited IQVIA March 2025 data showing JB grew 12% versus IPM growth of 8%.

Net profit for FY25 increased 19% to ₹660 crore. Operating cash flows were reported at ₹903 crore versus ₹801 crore in the previous year, and management stated operating cash flow to operating EBITDA at 83%.

On non-cash costs, ESOP expense was ₹55 crore (versus ₹42 crore), while depreciation increased from ₹138 crore in FY24 to ₹171 crore in FY25 due to amortisation of acquired and in-licensed brands.

Balance sheet updates and dividend

As of 31 March 2025, management reported net cash of ₹689 crore, up from ₹107 crore in the previous year. ROCE was cited at 32% versus 27% in FY24, while ROE was reported at 19.2% in FY25.

The board recommended a final dividend of ₹7 per share, resulting in a total dividend of ₹15.50 per share including an interim dividend of ₹8.50 per share.

Stock snapshot and key ratios cited

A data row included in the input for “J B Chemicals &” listed a current price of ₹1,890.05, P/E of 42.05, market capitalisation of ₹29,626.57 crore, and dividend yield of 0.82%. The same row also showed ROCE of 25.90%, price-to-book of 7.95, return on assets of 15.63%, and debt-to-equity of 0.01.

Because these ratios can vary by update cycle and data provider, investors typically reconcile them with the latest exchange filings and investor presentation for the same period.

Key negatives highlighted in the provided notes

The supplied notes flagged a few pressure points to track: international business growth was limited to 4% for the full year with challenges in South Africa and BGX segments; the API business has been declining over the past two years; and the trade generics segment remained negligible. The notes also mentioned potential risks around the Rantac product, while stating that no ban has been implemented.

Table: Q4 FY25 consolidated highlights mentioned in the text

Table: Income statement snapshot shared with BSE attribution

Data source as stated in the provided text: BSE, company announcements.

Market impact and why the quarter matters

The quarter showed JB Pharma’s ability to expand profitability while growing faster than the broader domestic market, supported by gross margin improvement and lower finance costs. The sharp fall in finance costs, from ₹9 crore to ₹1 crore year-on-year for the quarter, also aligned with management’s disclosure of higher net cash at year-end.

At the same time, sequential softness (including the QoQ decline cited in some summaries) and the set of risks noted around select international segments and the API business indicate that headline growth needs to be assessed alongside mix and sustainability. Investors will likely focus on whether India branded formulations can keep delivering above-market growth, and whether international execution improves beyond the FY25 growth rate of 4% cited for the segment.

Conclusion

JB Pharma closed Q4 FY25 with year-on-year revenue growth of about 10% and net profit around ₹146 crore, while expanding margins and lowering finance costs. The next set of updates will be watched for domestic growth momentum, international acceleration, and follow-through on cash generation and capital efficiency trends indicated for FY25.